Tx PMW ER+/HER2-neg, asymptomatic mets after 3 years adj AI?
What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, higher-volume metastases after receiving adjuvant anastrozole for 3 years?
Bachelot T et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30(22):2718-24. Abstract
Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9. Abstract
Campone M et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. Eur J Cancer 2013;49(12):2621-32. Abstract
Campos SM et al. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009;9(1):39. Abstract
Dees EC et al. Improving endocrine therapy for breast cancer: It's not that simple. J Clin Oncol 2013;10;31(2):171-3. Abstract
Martin LA et al. mTOR inhibitors in advanced breast cancer: Ready for prime time? Cancer Treat Rev 2013;39(7):742-52. Abstract